We are analyzing https://link.springer.com/article/10.1007/s00432-010-0957-x.

Title:
Characteristics of triple-negative breast cancer | Journal of Cancer Research and Clinical Oncology
Description:
Background Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking similarities with basal-like breast cancers (BBC), so a number of studies considered them being the same. The purpose of this review is to summarise the latest findings on TNBC concerning its relation and delineation to BBC, discuss the developmental pathways involved and address clinical implications for this complex type of breast cancer. Methods The recent literature from PubMed and Medline databases was reviewed. Results Not all TNBC are of the intrinsic BBC subtype (nonbasal (NB)-TNBC), nor are all BBC triple-negative (non-triple-negative (NTN)-BBC). There is increasing evidence that a triple-negative, basal-like breast cancer (TNBBC) subtype develops mainly through a BRCA1-related pathway. Somatic mutations that contribute to NTN-BBC and NB-TNBC development are possibly not related to this pathway, but may occur randomly due to increased genomic instability in these tumours. Several therapeutic options exist for TNBBC, which exhibited promising results in recent clinical trials. Cytotoxic therapies, e.g. combined treatment with anthracyclines or taxanes, achieved good tumour regression rates in the neo-adjuvant setting, but also showed considerable recurrence during the first 5 years after therapy. Targeted therapy options involve PARP1 and EGFR inhibition, although both approaches still need further investigation. Conclusions TNBC and BBC are not the same disease entity. The TNBBC subtype shows the largest homogeneity in terms of tumour development, prognosis and clinical intervention options.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Link.springer.com might be cashing in, but we can't detect the method they're using.

Keywords {🔍}

breast, cancer, google, scholar, article, pubmed, cas, expression, tnbbc, tnbc, brca, triplenegative, tumours, basallike, tumour, parp, gene, subtype, subtypes, patients, therapy, egfr, prognosis, cells, survival, bbc, pathway, response, studies, receptor, res, similar, compared, cell, clin, clinical, growth, phenotype, cancers, therapeutic, treatment, found, inhibitors, oncol, results, mutations, dna, factor, agents, development,

Topics {✒️}

high/p27 low/p53+/glomeruloid-microvascular-proliferation+ gefitinib-resistant mda-mb-468 cells article download pdf brca1-deficient mammary tumors triple-negative breast cancers basal/myoepithelial mammary cells brca1-mutated cell lines dna double-strand break brca1-related breast cancers triple-negative breast cancer tumour-related death diminish brca1/2-mutated breast cancer node-negative breast cancer dna single-strand breaks triple-positive breast cancer hr-negative tumours clustered single-institution compilation compared prolong disease-free survival disease-free survival interval brca1-related breast cancer node-positive breast cancer hr-positive tumours clustered heavily pre-treated patients distant disease-free survival breast-cancer-specific survival anti-egfr antibody cetuximab newly diagnosed african-american y-box binding protein-1 early breast cancer cell-growth-activating pathways hr-positive/her2-negative increased proliferation activity pathologic complete response advanced breast cancer privacy choices/manage cookies poor disease-specific survival triple-negative group histo-morphological subdivision base excision repair brca1-related pathway leading tyrosine kinase activity egfr-positive breast tumours tjan-heijnen department stimulates tumour growth single-strand breaks histo-morphological characteristics metastatic colon cancer triple negative paradox triple-positive group promising therapeutic options

Questions {❓}

Bertucci F, Finetti P, Cervera N, Esterni B, Hermitte F, Viens P, Birnbaum D (2008) How basal are triple-negative breast cancers?
Burness ML, Grushko TA, Olopade OI (2010) Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker?
Inhibition of PARP1 leads to more single-strand breaks in all cells, so why is it a targeted therapy?
It will address the following questions: What is the relation between the basal-like subtype and TNBC?
Nishimura R, Arima N (2008) Is triple negative a prognostic factor in breast cancer?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Characteristics of triple-negative breast cancer
         description:Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking similarities with basal-like breast cancers (BBC), so a number of studies considered them being the same. The purpose of this review is to summarise the latest findings on TNBC concerning its relation and delineation to BBC, discuss the developmental pathways involved and address clinical implications for this complex type of breast cancer. The recent literature from PubMed and Medline databases was reviewed. Not all TNBC are of the intrinsic BBC subtype (nonbasal (NB)-TNBC), nor are all BBC triple-negative (non-triple-negative (NTN)-BBC). There is increasing evidence that a triple-negative, basal-like breast cancer (TNBBC) subtype develops mainly through a BRCA1-related pathway. Somatic mutations that contribute to NTN-BBC and NB-TNBC development are possibly not related to this pathway, but may occur randomly due to increased genomic instability in these tumours. Several therapeutic options exist for TNBBC, which exhibited promising results in recent clinical trials. Cytotoxic therapies, e.g. combined treatment with anthracyclines or taxanes, achieved good tumour regression rates in the neo-adjuvant setting, but also showed considerable recurrence during the first 5 years after therapy. Targeted therapy options involve PARP1 and EGFR inhibition, although both approaches still need further investigation. TNBC and BBC are not the same disease entity. The TNBBC subtype shows the largest homogeneity in terms of tumour development, prognosis and clinical intervention options.
         datePublished:2010-11-11T00:00:00Z
         dateModified:2010-11-11T00:00:00Z
         pageStart:183
         pageEnd:192
         license:https://creativecommons.org/licenses/by-nc/2.0
         sameAs:https://doi.org/10.1007/s00432-010-0957-x
         keywords:
            Triple-negative breast cancer (TNBC)
            Basal-like breast cancer (BBC)
            BRCA1
            Adjuvant treatment
            Patient outcome
            Oncology
            Cancer Research
            Internal Medicine
            Hematology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-010-0957-x/MediaObjects/432_2010_957_Fig1_HTML.gif
         isPartOf:
            name:Journal of Cancer Research and Clinical Oncology
            issn:
               1432-1335
               0171-5216
            volumeNumber:137
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tim C. de Ruijter
               affiliation:
                     name:Maastricht University Medical Centre
                     address:
                        name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Maastricht University Medical Centre
                     address:
                        name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jürgen Veeck
               affiliation:
                     name:Maastricht University Medical Centre
                     address:
                        name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Maastricht University Medical Centre
                     address:
                        name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Joep P. J. de Hoon
               affiliation:
                     name:Maastricht University Medical Centre
                     address:
                        name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
                     name:Maastricht University Medical Centre
                     address:
                        name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Manon van Engeland
               affiliation:
                     name:Maastricht University Medical Centre
                     address:
                        name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Vivianne C. Tjan-Heijnen
               affiliation:
                     name:Maastricht University Medical Centre
                     address:
                        name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Characteristics of triple-negative breast cancer
      description:Triple-negative breast cancers (TNBC) neither express hormone receptors, nor overexpress HER2. They are associated with poor prognosis, as defined by low five-year survival and high recurrence rates after adjuvant therapy. Overall, TNBC share striking similarities with basal-like breast cancers (BBC), so a number of studies considered them being the same. The purpose of this review is to summarise the latest findings on TNBC concerning its relation and delineation to BBC, discuss the developmental pathways involved and address clinical implications for this complex type of breast cancer. The recent literature from PubMed and Medline databases was reviewed. Not all TNBC are of the intrinsic BBC subtype (nonbasal (NB)-TNBC), nor are all BBC triple-negative (non-triple-negative (NTN)-BBC). There is increasing evidence that a triple-negative, basal-like breast cancer (TNBBC) subtype develops mainly through a BRCA1-related pathway. Somatic mutations that contribute to NTN-BBC and NB-TNBC development are possibly not related to this pathway, but may occur randomly due to increased genomic instability in these tumours. Several therapeutic options exist for TNBBC, which exhibited promising results in recent clinical trials. Cytotoxic therapies, e.g. combined treatment with anthracyclines or taxanes, achieved good tumour regression rates in the neo-adjuvant setting, but also showed considerable recurrence during the first 5 years after therapy. Targeted therapy options involve PARP1 and EGFR inhibition, although both approaches still need further investigation. TNBC and BBC are not the same disease entity. The TNBBC subtype shows the largest homogeneity in terms of tumour development, prognosis and clinical intervention options.
      datePublished:2010-11-11T00:00:00Z
      dateModified:2010-11-11T00:00:00Z
      pageStart:183
      pageEnd:192
      license:https://creativecommons.org/licenses/by-nc/2.0
      sameAs:https://doi.org/10.1007/s00432-010-0957-x
      keywords:
         Triple-negative breast cancer (TNBC)
         Basal-like breast cancer (BBC)
         BRCA1
         Adjuvant treatment
         Patient outcome
         Oncology
         Cancer Research
         Internal Medicine
         Hematology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00432-010-0957-x/MediaObjects/432_2010_957_Fig1_HTML.gif
      isPartOf:
         name:Journal of Cancer Research and Clinical Oncology
         issn:
            1432-1335
            0171-5216
         volumeNumber:137
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tim C. de Ruijter
            affiliation:
                  name:Maastricht University Medical Centre
                  address:
                     name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Maastricht University Medical Centre
                  address:
                     name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jürgen Veeck
            affiliation:
                  name:Maastricht University Medical Centre
                  address:
                     name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Maastricht University Medical Centre
                  address:
                     name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Joep P. J. de Hoon
            affiliation:
                  name:Maastricht University Medical Centre
                  address:
                     name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
                  name:Maastricht University Medical Centre
                  address:
                     name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Manon van Engeland
            affiliation:
                  name:Maastricht University Medical Centre
                  address:
                     name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Vivianne C. Tjan-Heijnen
            affiliation:
                  name:Maastricht University Medical Centre
                  address:
                     name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Cancer Research and Clinical Oncology
      issn:
         1432-1335
         0171-5216
      volumeNumber:137
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Maastricht University Medical Centre
      address:
         name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
      name:Maastricht University Medical Centre
      address:
         name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tim C. de Ruijter
      affiliation:
            name:Maastricht University Medical Centre
            address:
               name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
            name:Maastricht University Medical Centre
            address:
               name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
      name:Jürgen Veeck
      affiliation:
            name:Maastricht University Medical Centre
            address:
               name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
            name:Maastricht University Medical Centre
            address:
               name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
      name:Joep P. J. de Hoon
      affiliation:
            name:Maastricht University Medical Centre
            address:
               name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
            name:Maastricht University Medical Centre
            address:
               name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
      name:Manon van Engeland
      affiliation:
            name:Maastricht University Medical Centre
            address:
               name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
      name:Vivianne C. Tjan-Heijnen
      affiliation:
            name:Maastricht University Medical Centre
            address:
               name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Department of Pathology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
      name:Division of Medical Oncology, Department of Internal Medicine, GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands

External Links {🔗}(262)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

6.21s.

LINK . SPRINGER . COM {}